Перегляд вихідного коду сторінки Something You Haven't Heard About Vasopressin Receptor

Interestingly, we found a higher proportion of SMA+ cells in severe HLHS hearts compared with control hearts (representative images are given in Figure?4A). Quantification by immunofluorescence confirmed lower myocyte and capillary numbers and lower capillary density in HLHS samples compared with controls ( Figure?4C). In addition, capillary density was lower in advanced gestation HLHS fetuses [http://www.selleckchem.com/products/Perifosine.html Perifosine clinical trial] (>22 weeks) compared to those ��22 weeks of gestational age. This was seen in both moderate and severe HLHS hearts ( Figure?4D). In contrast, SMA+ cells increased from 10% in control hearts to approximately 70% in HLHS hearts (P  revealed a high proportion of SMA+/FSP1+ cells suggestive of proliferating myofibroblasts in areas of interstitial fibrosis in HLHS hearts (50% �� 2% in HLHS samples versus 2% �� 2% in controls, P [http://www.selleckchem.com/products/ly2835219.html see more] marker, and TCF21/POD1, an epithelial-mesenchymal transition marker, [http://en.wikipedia.org/wiki/Vasopressin_receptor Vasopressin Receptor] expression was seen primarily in the epicardium and not the myocardium of both control and HLHS hearts ( Supplemental Figure?S2). We did however find co-localization of the profibrotic cytokine TGFB1 with FSP1 in HLHS hearts ( Figure?5C) and TGF-��1 mRNA up-regulation by qPCR (P